News and Announcements
Novapep now has a complete Peptide Mimetic of Activated Protein C
- Published March 12, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Prof John Griffin of the Scripps Research Institute and a co-founder of Novapep has a developed a linked form of P1, which Novapep licensed in 2017, and P3. The bivalently linked peptide is called G10 and it generates synergistic anti-inflammatory and cytoprotective cell-signalling which is significantly greater than co-administered P1 and P3.
The Company has licensed the G10 PCT patent from the Scripps and Novapep has also filed a use patent for P1 in inflammatory skin disorders.
In 2020, Novapep undertook a P1 in atopic dermatitis study which showed that the P1 efficacy was as good as cortico steroids, but with none of the side effects. Professor Richard Payne, Novapep’s Chief Scientific Officer, is currently undertaking a study of G10 in atopic dermatitis and Professor Stuart Brierley will undertake animal studies of G10 in anti-inflammatory and analgesic colitis models of inflammatory bowel disease in Q2/2021.
Novapep is currently raising $500,000 on a pre-money valuation of $4.5 million to fund animal studies and regulatory activities towards a Phase 1 trial.
About Novapep Pty Ltd
Novapep was founded by Prof John Griffin of The Scripps Research Institute, San Diego and Jay Hennock, founder and CEO of Bioatrix, Sydney to develop new peptide structures, which are anti-inflammatory, cytoprotective and analgesic for the treatment of atopic dermatitis and psoriasis/inflammatory skin disorders (‘ISD’) and inflammatory bowel disease/irritable bowel syndrome (‘IBD’). Prof Richard Payne, University of Sydney, has recently become Novapep’s Chief Scientific Officer.
Novapep has been approached by two global pharmaceutical companies wishing to explore partnering/out-licensing. Before entering negotiations, the Company is seeking $500,000 to secure additional patents and animal study data.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
